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Background: The aim of this study was to investigate the role of pre-treatment aspartate 
aminotransferase-lynphocyte ratio (ALRI) as a predictor of prognosis and treatment efficacy 
in patients with metastatic colorectal cancer (mCRC) enrolled in the prospective multicenter 
randomized ITACa (Italian Trial in Advanced Colorectal Cancer) trial to receive first-line 
chemotherapy (CT) + bevacizumab (B) or CT alone.
Patients and methods: Patients randomly received CT+B or CT alone as first-line therapy. 
CT consisted of either FOLFOX4 or FOLFIRI  at the clinician’s  discretion.
Results: Out of the 284 patients enrolled, increased ALRI levels were associated with shorter 
PFS and OS (p,0.0001). At baseline, median PFS was 10.3 months (95% CI 9.4–12.0) and 
8.0 months (95 % CI 6.8–8.9), and median OS was 25.2 months (95 % CI 21.3–30.2) and 
18.8 months (95 % CI 16.6–21.7) for patients with low (,14) and high ($14) ALRI levels, 
respectively (HR 1.43, 95% CI 1.12–1.82, p=0.004; HR=1.51, 95% CI 1.17–1.96, p,0.001). 
Interaction tests on ALRI levels and treatment efficacy in the CT+B and the CT groups were 
statistically significant for PFS (p=0.0003), but not for OS (p=0.228).
Conclusion: Our results indicate that ALRI is a good prognostic and predictive marker for 
mCRC patients candidate for CT+B.
Keywords: metastatic colorectal cancer, bevacizumab, first line, prognosis, aspartate 
aminotransferase-lymphocyte ratio index, clinical outcome, rectal cancer
Introduction
Colorectal cancer (CRC) is the third most common cause of death from cancer in 
Western Europe and North America.1
Literature has shown the relationship between systemic chronic inflammation and 
various types of cancer, including CRC,2 as the activation of the inflammatory cascade 
by malignant tumors leads to apoptosis inhibition and angiogenesis promotion, eventu-
ally causing tumor genesis, proliferation, and metastasis.3,4
In clinical practice, physicians commonly test the liver enzyme aspartate amin-
otransferase (AST), without evidence of any correlation with the response to beva-
cizumab (B).
To our knowledge, no population-based study has yet been conducted on the prognostic 
value of baseline AST-lymphocyte ratio index (ALRI) in predicting progression-free sur-
vival (PFS) in CRC patients treated with B. We think that the ALRI is an important param-
eter that provides data after combining the inflammatory state with a hepatic index.
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We investigated the prognostic and predictive roles of 
baseline ALRI in metastatic CRC (mCRC) patients treated 
with first-line chemotherapy (CT)+B or CT alone in the 
Phase III prospective multicenter randomized ITACa trial 
(Italian Trial in Advanced Colorectal Cancer; EudraCT no 
2007-004539-44 and on ClinicalTrials.gov NCT01878422).5
Patients and methods
The iTaca trial
Patients randomly received CT+B or CT alone as first-line 
therapy. CT consisted of either FOLFOX4 (a 2-hour infusion 
of 85 mg/m2 oxaliplatin on day 1 and a 2-hour infusion of 
100 mg/m2 leucovorin followed by 400 mg/m2 bolus 5-FU 
and a 22-hour infusion of 600 mg/m2 5-FU on days 1–2 
every 2 weeks) or FOLFIRI (a 2-hour infusion of 100 mg/m2 
leucovorin followed by 400 mg/m2 bolus 5-FU and a 22-hour 
infusion of 600 mg/m2 5-FU on days 1–2 every 2 weeks with 
the addition of a 90-minute infusion of 180 mg/m2 irinotecan 
on day 1) at the clinician’s discretion. A 30–90-minute intra-
venous infusion of 5 mg/kg B was administered on day 1 of 
each 2-week cycle.
Treatment continued until either progressive disease 
(PD) or unacceptable toxicity or withdrawal of consent. 
Tumor assessment was performed before the start of treat-
ment and repeated every 8 weeks until PD. Responses were 
defined according to the Response Evaluation Criteria in 
Solid Tumors guidelines (per investigator assessment). The 
National Cancer Institute Common Toxicity Criteria were 
used for evaluating adverse events.
The ITACa trial was approved by the local ethics commit-
tee (Comitato Etico Area Vasta Romagna) on September 19, 
2007 and registered in our National Clinical Trials Observa-
tory (Osservatorio delle Sperimentazioni Cliniche) and in 
the European Clinical Trials Database (EudraCT no 2007-
004539-44) before patient recruitment began. Registration 
on ClinicalTrials.gov (NCT01878422) was not mandatory 
but was carried out at a later date (June 7, 2013). All patients 
provided written informed consent. The study was carried 
out in accordance with the Declaration of Helsinki under 
good clinical practice conditions and after full approval of 
the ethics committees of all participating centers (Comitato 
Etico Area Vasta Romagna e IRST, Comitato Etico Pro-
vinciale di Modena, Comitato Etico AUSL di Piacenza, 
Comitato Etico Interaziendale AOU “Maggiore della Carità” 
di Novara, Comitato Etico Interaziendale dell’A.S.O. Santa 
Croce e Carle di Cuneo, Comitato Etico della Provincia di 
Modena, Comitato Etico della Provincia di Ferrara, Comitato 
Etico Unico per la Provincia di Parma, Comitato Etico 
Indipendente Azienda USL di Bologna, Comitato Etico della 
ASL LE di Lecce, Comitato Etico Provinciale di Belluno per 
la Sperimentazione Clinica).
statistical analysis
PFS and overall survival (OS) were, respectively, the primary 
and one of the secondary endpoints of the ITACa study. 
Information on AST and lymphocyte counts from blood tests 
carried out at baseline (before systemic treatment) was col-
lected subsequently for the purpose of this post hoc analysis. 
ALRI was calculated as AST/lymphocyte count. The aim 
of this analysis was to evaluate the association between 
baseline ALRI levels and PFS and OS in the intent-to-treat 
population.
PFS was defined as the time from the date of random 
assignment to the date of either first documentation of PD, 
or last tumor evaluation, or death from any cause. Patients 
undergoing curative metastasectomy were censored at the 
date of surgery. OS was defined as the time from the date of 
random assignment to the date of death or last follow-up visit. 
PFS and OS were estimated by Kaplan–Meier method and 
curves were compared using the log rank test. Cox regres-
sion model was used to estimate HRs, their 2-sided 95% CI, 
and HR adjusted by center, baseline characteristics (gender, 
age, Eastern Cooperative Oncology Group performance 
status [ECOG PS], KRAS status, and tumor localization), 
CT regimen, and ITACa treatment. Cox regression model 
was also used to evaluate the effect on PFS and OS of the 
interaction between ALRI levels and treatment, including 
ALRI levels, treatment, and treatment-by-ALRI levels. X-tile 
3.6.1 software (Yale University, New Haven, CT, USA) was 
used for bioinformatics analysis of baseline data to determine 
the cutoff value for pretreatment levels of ALRI. ALRI $14 
was considered as a high level.
Patient characteristics were compared with χ2 test, and 
median values were compared using nonparametric ranking 
test (median test). All p-values were based on 2-sided testing. 
Statistical analyses were performed using SAS statistical 
software version 9.4 (SAS Inc., Cary, NC, USA).
Results
Patient characteristics
Between November 14, 2007 and March 6, 2012, 284 patients 
diagnosed with CRC were available for baseline AST and 
lymphocyte analysis (Figure 1); the study sample included 
170 (59.8%) males and 114 (40.2%) females with a median 
age at diagnosis of 66 years (range 33–83). Median follow-up 
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was 36 months (range 1–65). Overall, median PFS was 9.1 
(95% CI 8.4–9.8) and median OS was 21.4 months (95% CI 
19.9–24.5). The 2 groups of patients were comparable with 
regard to age, gender, tumor localization, stage at diagnosis, 
KRAS status, and ITACa treatment. A considerable 
proportion of patients with high ALRI had performance 
status 1–2.
alri values and clinical outcome in all 
patients
Considering ALRI as a continuous variable, we observed that 
increased ALRI levels were associated with decreased PFS 
(HR 1.02, 95% CI 1.01–1.02, p,0.0001) and OS (HR 1.02, 
95% CI 1.02–1.03, p,0.0001).
The 2 groups of patients were comparable for all the major 
clinical characteristics investigated, except for EOCG and 
CT regimen (Table 1).
At baseline, median PFS was 10.3 months (95% CI 
9.4–12.0) and 8.0 months (95% CI 6.8–8.9) for patients 
with low (,14) and high ($14) ALRI levels, respectively 
(HR 1.43, 95% CI 1.12–1.82, p=0.004) (Figure 2A). 
Median OS was 25.5 months (95% CI 21.3–30.2) and 
18.8 months (95% CI 16.6–21.7) for patients with low 
and high baseline ALRI levels, respectively (HR 1.51, 
95% CI 1.17–1.96, p,0.001) (Figure 2B). ALRI, AST, 
and lymphocyte values were associated with different 
toxicities (Table 2).
Following adjustment for clinical covariates (age, gender, 
ECOG, tumor localization, CT regimen, KRAS status, ITACa 
treatment, and LDH level and liver metastasis), multivariate 
analysis confirmed ALRI as an independent prognostic 
factor for predicting PFS (HR 1.35, 95% CI 1.02–1.79, 
p=0.034) and OS (HR 1.35, 95% CI 1.01–1.83 p=0.048) 
(Table 3).
Figure 1 Flow chart of the study.
Abbreviation: alri, aspartate aminotransferase-lymphocyte ratio index.
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Table 1 Patient characteristics (n=284)
Patient characteristics ALRI p-values
,14 $14
n (%) n (%)
Median age, years (range) 66 (34–83) 65 (33–81) 0.771
gender 0.904
Male 86 (60.6) 84 (59.2)
Female 56 (39.4) 58 (40.8)
Performance status ecOg 0.005
0 123 (86.6) 103 (72.5)
1–2 19 (13.4) 39 (27.5)
Tumor localization 0.893
rectum 37 (26.1) 38 (26.8)
colon 105 (73.9) 104 (73.2)
stage at diagnosis 0.646
i–iii 35 (25.9) 31 (22.8)
iV 100 (74.1) 105 (77.2)
cT regimen 0.028
FOlFOX4 97 (68.3) 78 (54.9)
FOlFiri 45 (31.7) 64 (45.1)
Kras statusa 0.387
Wild type 95 (66.9) 87 (61.3)
Mutated 47 (33.1) 55 (38.7)
iTaca treatment 0.812
cT+B 67 (47.2) 70 (49.3)
cT 75 (52.8) 72 (50.7)
Note: aMandatory as consequence of amendment no 1 of May 3, 2009.
Abbreviations: alri, aspartate aminotransferase-lymphocyte ratio index; B, 
bevaci zumab; cT, chemotherapy; ecOg, eastern cooperative Oncology group; 
iTaca, italian Trial in advanced colorectal cancer; n, number.
Figure 2 Kaplan–Meier curves of PFs (A), Os (B).
Abbreviations: alri, aspartate aminotransferase-lymphocyte ratio index; PFs, progression-free survival; Os, overall survival.
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alri values and clinical outcome in 
patients treated with cT+B
Considering ALRI as a continuous variable, we observed also 
in patients undergoing CT+ B that increased ALRI levels were 
associated with decreased PFS (HR 1.01, 95% CI 1.01–1.02, 
p=0.001) and OS (HR 1.02, 95% CI 1.01–1.03, p,0.0001).
At baseline, median PFS was 11.3 months (95% CI 
9.1–13.4) and 9.2 months (95% CI 6.8–11.3) for patients with 
low and high ALRI levels, respectively (p=0.304; HR 1.20, 
95% CI 0.85–1.69, p=0.304) (Figure 3A). On the other hand, 
median OS was 22.7 and 15.9 months for patients with low 
and high baseline ALRI, respectively (HR 1.36, 95% CI 
0.95–1.96, p=0.095) (Figure 3B).
alri values and clinical outcome in 
patients treated with cT alone
Considering ALRI as a continuous variable, we observed 
also in patients undergoing CT alone that increased ALRI 
levels were associated with decreased PFS (HR 1.04, 
95% CI 1.03–1.05, p,0.0001) and OS (HR 1.03, 95% 
CI 1.02–1.04, p,0.0001).
At baseline, median PFS was 10.0 months (95% CI 
9.0–11.8) and 7.0 months (95% CI 5.9–8.4) for patients with 
low and high ALRI levels, respectively (p=0.002; HR 1.71, 
95% CI 1.22–2.41, p=0.002) (Figure 3C). Median OS was 
27.1 and 20.2 months for patients with low and high base-
line ALRI levels, respectively (p=0.007; HR 1.64, 95% CI 
1.14–2.36, p=0.007) (Figure 3D).
Interaction tests on ALRI levels and treatment efficacy in 
the CT+B and CT only groups were statistically significant 
for PFS (p=0.0003) but not for OS (p=0.228).
Figure 4 shows the Kaplan–Meier curves of PFS of 
patients treated with CT+B and CT alone with respect to 
ALRI levels.
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Table 2 comparison of median values of alri, asT and lymphocytes as a function of toxicity
 Number 
of patients
ALRI median 
value (range)
p-values AST median 
value (range)
p-values Lymphocyte median 
value (range)
p-values
nausea 0.623 0.970 0.733
g0 153 14.9 (1.3–172.3) 21 (9–193) 1.55 (0.43–10.40)
g1+g2 124 13.2 (3.2–141.0) 21 (8–100) 1.64 (0.58–10.51)
g3+g4 7 15.0 (9.3–28.6) 24 (14–28) 1.57 (0.98–2.07)
Vomiting 0.852 0.929 0.687
g0 217 14.0 (2.1–172.3) 21 (9–193) 1.63 (0.43–5.85)
g1+g2 60 13.8 (1.4–82.6) 20 (8–100) 1.50 (0.87–10.51)
g3+g4 7 15.0 (9.2–29.7) 24 (16–35) 1.60 (0.82–2.07)
Diarrhea 0.032 0.194 0.540
g0 150 14.9 (3.0–172.3) 22 (9–193) 1.57 (0.43–10.51)
g1+g2 117 13.9 (1.3–141.0) 21 (10–88) 1.57 (0.61–10.40)
g3+g4 17 11.4 (4.3–33.3) 20 (8–43) 1.93 (0.72–3.75)
stomatitis 0.230 0.073 0.468
g0 220 14.0 (1.3–172.3) 20 (8–193) 1.55 (0.43–10.51)
g1+g2 57 13.8 (4.8–102.3) 23 (11–96) 1.64 (0.77–4.75)
g3+g4 7 21.0 (12.6–31.0) 30 (17–83) 1.57 (1.25–2.68)
Fatigue 0.010 0.0004 0.220
g0 159 13.2 (2.1–169.8) 20 (8–117) 1.54 (0.43–5.85)
g1+g2 106 14.4 (1.3–141.0) 22 (9–142) 1.64 (0.56–10.51)
g3+g4 19 20.1 (5.1–172.3) 28 (11–193) 1.46 (0.86–2.44)
anemia 0.221 0.187 0.857
g0 224 13.8 (1.3–172.3) 21 (8–193) 1.60 (0.43–10.51)
g1+g2 54 17.1 (3.5–102.3) 23 (10–96) 1.53 (0.72–3.75)
g3+g4 6 11.4 (4.2–55.4) 16 (12–51) 1.63 (0.92–2.87)
neutropenia 0.791 0.683 0.182
g0 101 14.8 (3.0–172.3) 20 (9–193) 1.51 (0.43–3.50)
g1+g2 58 12.5 (3.5–70.5) 20 (10–117) 1.67 (0.58–3.75)
g3+g4 124 14.7 (1.3–102.3) 22 (8–100) 1.57 (0.72–10.51)
Thrombocytopenia 0.595 0.367 0.691
g0 219 14.1 (1.3–172.3) 21 (8–193) 1.60 (0.43–10.51)
g1+g2 59 13.2 (6.3–102.3) 23 (12–88) 1.60 (0.86–3.98)
g3+g4 6 19.3 (6.3–33.3) 24 (17–33) 1.47 (0.72–3.15)
Febrile neutropenia 0.515 0.820 0.202
g0 278 14.1 (1.3–172.3) 21 (8–193) 1.57 (0.43–10.51)
g1+g2 2 10.3 (3.5–17.0) 20 (10–30) 2.32 (1.76–2.89)
g3+g4 4 11.5 (8.7–17.2) 23 (18–28) 1.90 (1.57–2.36)
hemorrhage 0.863 0.713 0.596
g0 249 13.9 (1.3–172.3) 21 (8–193) 1.57 (0.43–10.51)
g1+g2 35 15.6 (4.3–74.7) 22 (9–142) 1.68 (0.97–3.75)
g3+g4 0 – – –
hypertension 0.096 0.429 0.077
g0 226 14.7 (1.3–172.3) 21 (8–193) 1.57 (0.43–10.40)
g1+g2 51 11.2 (2.0–82.6) 20 (10–100) 1.69 (0.77–10.51)
g3+g4 7 17.1 (6.4–102.3) 25 (16–88) 1.46 (0.86–2.97)
Thrombosis 0.379 0.335 0.361
g0 232 14.1 (1.3–172.3) 21 (8–193) 1.57 (0.43–10.51)
g1+g2 19 14.6 (4.8–82.6) 21 (12–100) 1.31 (0.56–2.55)
g3+g4 33 11.9 (3.0–50.0) 20 (9–73) 1.73 (0.72–3.50)
Proteinuria 0.001 0.005 0.514
g0 221 13.2 (1.4–169.8) 20 (8–117) 1.60 (0.43–10.51)
g1+g2 63 16.9 (4.2–172.3) 25 (11–193) 1.60 (0.61–3.50)
g3+g4 0 – – –
neurologic system 0.028 0.168 0.044
g0 183 15.0 (1.3–172.3) 22 (8–193) 1.58 (0.43–10.40)
g1+g2 83 13.9 (3.2–102.3) 20 (10–88) 1.55 (0.58–10.51)
g3+g4 18 9.8 (3.5–50.0) 18 (10.83) 1.88 (1.17–4.75)
Abbreviations: alri, aspartate aminotransferase-lymphocyte ratio index; asT, aspartate aminotransferase.
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Table 3 Multivariate analysis of PFs and Os
 PFS OS
HR (95% CI) p-values HR (95% CI) p-values
alri ($14 vs ,14) 1.35 (1.02–1.79) 0.034 1.35 (1.01–1.83) 0.048
age (continuous variable) 1.00 (0.98–1.01) 0.818 0.99 (0.98–1.01) 0.222
gender (male vs female) 0.81 (0.62–1.07) 0.139 0.87 (0.65–1.16) 0.349
ecOg Ps (1–2 vs 0) 1.33 (0.94–1.88) 0.109 2.18 (1.50–3.18) ,0.0001
Tumor localization (colon vs rectum) 0.98 (0.72–1.34) 0.908 1.09 (0.79–1.51) 0.585
cT regimen (FOlFiri vs FOlFOX4) 1.27 (0.95–1.70) 0.104 1.07 (0.79–1.44) 0.659
Kras status (mutated vs wild type) 0.98 (0.75–1.30) 0.910 1.17 (0.87–1.56) 0.296
iTaca treatment (cT+B vs cT) 0.84 (0.64–1.11) 0.230 1.19 (0.89–1.59) 0.228
lDh (.Unl vs #Unl) 1.20 (0.90–1.60) 0.202 1.30 (0.96–1.76) 0.095
liver metastasis
Only 1 lesion ,5 cm vs no liver mts 0.55 (0.28–1.06) 0.076 0.62 (0.30–1.27) 0.191
Multiple liver lesions or 1 liver lesion $5 cm vs no liver mts 1.09 (0.78–1.52) 0.624 1.15 (0.81–1.64) 0.437
Abbreviations: alri, aspartate aminotransferase-lymphocyte ratio index; cT, chemotherapy; ecOg Ps, eastern cooperative Oncology group performance status; iTaca, 
italian Trial in advanced colorectal cancer; lDh, lactate dehydrogenase; PFs, progression-free survival; Os, overall survival; Unl, upper normal limit.
Figure 3 Kaplan–Meier curves of PFs (A) and Os (B) of patients treated with cT+B, Kaplan–Meier curves of PFs (C) and Os (D) in patients treated with cT.
Abbreviations: alri, aspartate aminotransferase-lymphocyte ratio index; B, bevacizumab; cT, chemotherapy; Os, overall survival; PFs, progression-free survival.
1.00
0.80
0.60
0.40
0.20
0.00
0 6
≥14
<14
12 18 24
Months
PF
S
30
A 1.00
0.80
0.60
0.40
0.20
0.00
0 6
≥14
<14
12 18 24
Months
O
S
30 36 42 48
B
No pts at risk
67ALRI <14 52 31 15 10 6
ALRI ≥14 70 47 25 12 8 5
67 53 43 32 25 19
70 44
61
55 30 26 21 17
17
13
13
10
1.00
0.80
0.60
0.40
0.20
0.00
0 6
≥14
<14
12 18 24
Months
PF
S
3630
C 1.00
0.80
0.60
0.40
0.20
0.00
0 6
≥14
<14
12 18 24
Months
O
S
30 36 42 48
D
No pts at risk
75ALRI <14 57 29 19 15 9
ALRI ≥14 72 43 11 6 4
12
3 3
75 63 52 40 33 30
72 56
71
63 41 27 11 9
19
6
18
6
OncoTargets and Therapy 2018:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
5267
Prognostic role of alri in patients with mcrc
Table 4 liver disease and median value of asT
Number 
of patients
AST median 
value (range)
p-values Lymphocyte median 
value (range)
p-values ALRI median 
value (range)
p-values
Overall ,0.0001 0.229 0.003
no liver disease +1 single liver 
lesion ,5 cm
81 17 (9–117) 1.51 (0.56–10.40) 12.70 (1.35–80.15)
Multiple lesions (including 1 liver) 
or 1 single hepatic lesion $5 cm
203 23 (8–193) 1.62 (0.43–10.51) 15.20 (2.05–172.32)
Abbreviations: alri, aspartate aminotransferase-lymphocyte ratio index; asT, aspartate aminotransferase.
Figure 4 Kaplan–Meier curves of PFs of patients treated with cT+B and cT on the 
basis of alri levels.
Abbreviations: alri, aspartate aminotransferase-lymphocyte ratio index; B, 
bevacizumab; cT, chemotherapy; PFs, progression-free survival.
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asT and lymphocyte values and clinical 
outcome in all patients
Considering ALRI as a continuous variable, we observed that 
increased AST levels were associated with decreased PFS 
(HR 1.01, 95% CI 1.01–1.02, p=0.0002) and OS (HR 1.02, 
95% CI 1.01–1.02, p,0.0001). Among basal characteristics, 
we observed that AST levels were higher in patients with 
liver disease (Table 4).
Considering lymphocyte as a continuous variable, we 
observed that increased lymphocyte levels were associated 
with decreased PFS (HR 0.84, 95% CI 0.72–0.99, p=0.036), 
but not OS (HR 0.91, 95% CI 0.77–1.06, p=0.214).
Discussion
Our study showed that high levels of ALRI at baseline were 
associated with shorter PFS and OS than low ALRI levels. 
To our knowledge, our study is the first to have assessed the 
prognostic value of ALRI in patients with CRC, potentially 
representing a noninvasive predictor of prognosis for CRC 
patients. However, the cutoff value of ALRI in our report 
was different from what was previously reported in other 
diseases.6,7 ALRI was evaluated in particular in patients with 
hepatocellular carcinoma, as levels of AST are higher and 
lymphocyte levels are lower due to cirrhosis.
AST plays a role in the metabolism of amino acids in the 
liver, and thus its increase becomes a biochemical marker 
of liver failure.8 Lymphocytes play a role in the antitumor 
immune response, and their presence relates to a reduced risk 
of relapse in several situations.9 Increased serum AST may 
be a result of the progression of liver diseases, as intracel-
lular AST is released when the hepatic parenchymal cells are 
injured. Conversely, decreased lymphocytes can reduce the 
antitumor immunity of the patients. For this reason, ALRI 
may be used for predicting response and OS.
B, a recombinant humanized monoclonal antibody 
directed against vascular endothelial growth factor, was 
found to improve survival in both first- and second-line 
settings when added to CT.10 There is no current validated 
clinical or biological factor that can predict response to B. 
A positive result to the interaction test indicates that the ALRI 
index may be predictive of B efficacy. We hypothesize that B 
may be capable of contrasting the negative predictive value 
of high baseline levels of ALRI. In fact, among patients with 
high ALRI levels, PFS was lower in those treated with CT 
alone than in those treated with CT+B.
With regard to toxicity, it is noteworthy that high values 
of ALRI and AST were mostly associated with a higher 
incidence of fatigue, probably as result of a greater amount 
of liver disease at baseline, which may induce higher chemo-
related toxicity.
In conclusion, pretreatment levels of ALRI may consti-
tute a marker of aggressiveness in CRC patients. Elevated 
ALRI levels prior to treatment seem to be indicators of poor 
prognosis.
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